Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.

  title={Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.},
  author={Abby L. Parrill and Uniqua Echols and Tran Que Nguyen and T T Pham and Adrienne B Hoeglund and Daniel L. Baker},
  journal={Bioorganic & medicinal chemistry},
  volume={16 4},
Autotaxin (ATX, NPP-2) catalyzes the conversion of lysophosphatidyl choline (LPC) to lysophosphatidic acid (LPA), a mitogenic cell survival factor that stimulates cell motility. The high expression of both ATX and receptors for LPA in numerous tumor cell types has produced substantial interest in exploring ATX as an anticancer chemotherapeutic target. ATX inhibitors reported to date are analogs of LPA, a phospholipid, and are more hydrophobic than is typical of orally bioavailable drugs. This… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 14 extracted citations

S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool.

The Journal of pharmacology and experimental therapeutics • 2008
View 3 Excerpts
Highly Influenced

Aiming drug discovery at lysophosphatidic acid targets

British journal of pharmacology • 2010
View 2 Excerpts

Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation.

Proceedings of the National Academy of Sciences of the United States of America • 2010
View 1 Excerpt

Similar Papers

Loading similar papers…